BMY's February Rally Highlights Growth Offsetting Legacy, But Margin Risks Persist

What happened

Bristol Myers Squibb's stock performed strongly in February, as reported by The Motley Fool, driven by its growth portfolio offsetting declines in legacy treatments and progress in developmental programs. DeepValue's analysis confirms this dynamic, with Growth Portfolio revenue up 17% in FY25 against a 15% drop in Legacy Portfolio, supporting the transition narrative. However, SEC filings reveal significant policy headwinds, including IRA-mandated price resets for Eliquis effective January 2026 and the end of volume caps for Revlimid generics on January 31, 2026. Management's 2026 guidance assumes Eliquis grows 10-15% while maintaining a 69-70% gross margin, a delicate balance that will be tested in upcoming quarters. The stock's recent gain thus reflects surface-level optimism while underlying risks from government pricing and margin pressure remain unaddressed.

Implication

The growth portfolio's ability to offset legacy declines is substantiated but faces immediate tests from U.S. healthcare policy changes that could erode profitability. Eliquis, contributing over $14 billion in revenue, is now subject to IRA maximum fair pricing and Medicaid concessions, potentially forcing volume growth at the expense of margins. Simultaneously, Revlimid's accelerated post-January 2026 decline adds revenue pressure, requiring sustained high growth from newer assets. Management's incentive structure, which excludes loss-of-exclusivity brands, may encourage prioritizing short-term sales over margin durability. Consequently, while the stock rally acknowledges operational progress, a cautious approach is warranted until Q2 2026 results confirm gross margin stability and Eliquis performance against guidance.

Thesis delta

The news article reinforces the positive narrative of portfolio transition but does not alter the core investment thesis; BMY remains in a precarious bridge year with policy-sensitive economics. The February stock increase aligns with the base scenario but does not mitigate the risks of margin degradation or Revlimid erosion, reinforcing the 'WAIT' rating until observable proof points are met in the next quarter.